Stem cell therapy for type-2 diabetes: keeping the pedal to the metal to deliver translation to the clinic.
作者信息
Yang Ning, Hickson LaTonya J, Lerman Lilach O
机构信息
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Division of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
出版信息
Expert Opin Biol Ther. 2024 Nov;24(11):1183-1187. doi: 10.1080/14712598.2024.2422358. Epub 2024 Oct 31.
Abstract
摘要
相似文献
1
Stem cell therapy for type-2 diabetes: keeping the pedal to the metal to deliver translation to the clinic.2型糖尿病的干细胞疗法：全力以赴推动其临床转化。
Expert Opin Biol Ther. 2024 Nov;24(11):1183-1187. doi: 10.1080/14712598.2024.2422358. Epub 2024 Oct 31.
2
Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells.2 型糖尿病病程和肥胖改变了自体骨髓来源间充质干细胞/基质细胞移植的疗效。
Stem Cells Transl Med. 2021 Sep;10(9):1266-1278. doi: 10.1002/sctm.20-0506. Epub 2021 Jun 3.
3
Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis.间充质干细胞移植治疗 1 型和 2 型糖尿病的疗效：一项荟萃分析。
Stem Cell Res Ther. 2021 May 6;12(1):273. doi: 10.1186/s13287-021-02342-5.
4
Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review.迈向2型糖尿病标准化干细胞治疗：一项系统评价
Curr Stem Cell Res Ther. 2018;13(6):476-488. doi: 10.2174/1574888X13666180502143657.
5
Efficacy of Stem Cell Application in Diabetes Mellitus: Promising Future Therapy for Diabetes and Its Complications.干细胞应用于糖尿病的疗效：糖尿病及其并发症未来有前景的治疗方法。
Cureus. 2021 Feb 26;13(2):e13563. doi: 10.7759/cureus.13563.
6
A review of clinical trials: mesenchymal stem cell transplant therapy in type 1 and type 2 diabetes mellitus.临床试验综述：1型和2型糖尿病中的间充质干细胞移植疗法
Am J Stem Cells. 2018 Oct 1;7(4):82-93. eCollection 2018.
7
Administration of Tonsil-Derived Mesenchymal Stem Cells Improves Glucose Tolerance in High Fat Diet-Induced Diabetic Mice via Insulin-Like Growth Factor-Binding Protein 5-Mediated Endoplasmic Reticulum Stress Modulation.扁桃体来源间充质干细胞通过胰岛素样生长因子结合蛋白 5 介导的内质网应激调节改善高脂肪饮食诱导的糖尿病小鼠的葡萄糖耐量。
Cells. 2019 Apr 23;8(4):368. doi: 10.3390/cells8040368.
8
The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis.干细胞治疗糖尿病的临床疗效与安全性：一项系统评价与荟萃分析
Aging Dis. 2020 Feb 1;11(1):141-153. doi: 10.14336/AD.2019.0421. eCollection 2020 Feb.
9
Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway.褪黑素治疗通过 PI3K/AKT 信号通路改善 II 型糖尿病小鼠模型中的人脐带间充质干细胞治疗。
Stem Cell Res Ther. 2022 Apr 12;13(1):164. doi: 10.1186/s13287-022-02832-0.
10
Characterizing the degeneration of nuclear membrane and mitochondria of adipose-derived mesenchymal stem cells from patients with type II diabetes.表征 II 型糖尿病患者脂肪间充质干细胞的核膜和线粒体退化。
J Cell Mol Med. 2021 May;25(9):4298-4306. doi: 10.1111/jcmm.16484. Epub 2021 Mar 23.
本文引用的文献
1
Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications.糖尿病及其并发症中间充质干细胞衍生的外泌体。
Cell Death Dis. 2024 Apr 17;15(4):271. doi: 10.1038/s41419-024-06659-w.
2
Mesenchymal Stem Cell Therapies Approved by Regulatory Agencies around the World.全球监管机构批准的间充质干细胞疗法
Pharmaceuticals (Basel). 2023 Sep 21;16(9):1334. doi: 10.3390/ph16091334.
3
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).间质基质细胞（ORBCEL-M）治疗糖尿病肾病的安全性和初步疗效：一项随机临床试验（NEPHSTROM）。
J Am Soc Nephrol. 2023 Oct 1;34(10):1733-1751. doi: 10.1681/ASN.0000000000000189. Epub 2023 Aug 10.
4
Function and mechanism of mesenchymal stem cells in the healing of diabetic foot wounds.间质干细胞在糖尿病足伤口愈合中的作用和机制。
Front Endocrinol (Lausanne). 2023 Mar 16;14:1099310. doi: 10.3389/fendo.2023.1099310. eCollection 2023.
5
Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis.间充质基质细胞疗法与 SGLT2 抑制剂和常规治疗糖尿病肾病的成本效益分析。
PLoS One. 2022 Nov 4;17(11):e0274136. doi: 10.1371/journal.pone.0274136. eCollection 2022.
6
Human Umbilical Cord Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Ameliorated Insulin Resistance in Type 2 Diabetes Mellitus Rats.人脐带间充质干细胞来源的小细胞外囊泡改善2型糖尿病大鼠的胰岛素抵抗
Pharmaceutics. 2022 Mar 16;14(3):649. doi: 10.3390/pharmaceutics14030649.
7
Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton's Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial.同种异体牙髓间充质干细胞 2 次阴茎内注射治疗糖尿病勃起功能障碍患者的安全性和有效性：1/2 期临床试验。
Urol Int. 2021;105(11-12):935-943. doi: 10.1159/000517364. Epub 2021 Aug 12.
8
Mesenchymal Stem Cells: An Excellent Candidate for the Treatment of Diabetes Mellitus.间充质干细胞：治疗糖尿病的理想候选者。
Int J Endocrinol. 2021 May 28;2021:9938658. doi: 10.1155/2021/9938658. eCollection 2021.
9
From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Progress and Challenges.从间充质基质/干细胞到胰岛素分泌细胞：进展与挑战。
Stem Cell Rev Rep. 2020 Dec;16(6):1156-1172. doi: 10.1007/s12015-020-10036-3.
10
Mesenchymal stromal cells pretreated with pro-inflammatory cytokines promote skin wound healing through VEGFC-mediated angiogenesis.预处理的间充质基质细胞通过 VEGFC 介导的血管生成促进皮肤伤口愈合。
Stem Cells Transl Med. 2020 Oct;9(10):1218-1232. doi: 10.1002/sctm.19-0241. Epub 2020 Jun 13.
Zotero 插件